

Quick reference guide

Machine perfusion systems and cold static storage of kidneys from deceased donors

Guidance

This technology appraisal covers the available methods of storing kidneys from deceased donors – that is, LifePort kidney transporter, Belzer University of Wisconsin (Belzer UW) storage solution and Marshall's hypertonic citrate solution. No cost data were available to the Committee to allow recommendations to be made for the RM3 renal preservation system.

- 1 Machine perfusion using the LifePort kidney transporter and cold static storage using Belzer UW storage solution or Marshall's hypertonic citrate solution are recommended as options for the storage of kidneys from deceased donors.
- 2 The choice of storage method should take into account clinical and logistical factors in both the retrieval teams and transplant centres. In situations where different storage methods are considered equally appropriate, then the least costly should be used.

Implementation tools

NICE has developed tools to help organisations put this guidance into practice (listed below). These are available on our website (www.nice.org.uk/TA165).

- Audit support for monitoring local practice.
- A costing statement explaining the resource impact of this guidance.

Further information

Ordering information

You can download the following documents from www.nice.org.uk/TA165

- A quick reference guide (this document) – the recommendations.
- 'Understanding NICE guidance' – a summary for patients and carers.
- The NICE guidance.
- Details of all the evidence that was looked at and other background information.

For printed copies of the quick reference guide or 'Understanding NICE guidance', phone NICE publications on 0845 003 7783 or email publications@nice.org.uk and quote:


- N1783 (quick reference guide)
- N1784 ('Understanding NICE guidance').

Related NICE guidance

There is no related guidance for these technologies. For information about NICE guidance that has been issued or is in development, see the website (www.nice.org.uk).

Updating the appraisal

This technology appraisal will be considered for review in August 2010. Information about the progress of a review will be available at www.nice.org.uk/TA165



This guidance represents the view of NICE, which was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

© National Institute for Health and Clinical Excellence, 2009. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.